文献速递MDS 与骨髓增殖性肿瘤

fedratinib治疗既往接受ruxolitinib的骨髓纤维化患者的疗效与安全性(FREEDOM2):多中心、开放标签、随机对照3期试验结果

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2024-09-09

FREEDOM2为多中心开放标签随机对照3期试验,纳入对ruxolitinib复发/难治或不耐受的中危-2或高危骨髓纤维化患者,按2:1随机接受fedratinib 400 mg/日或最佳可用治疗(BAT)。第6周期末脾体积缩小≥35%(SVR35)者fedratinib组48/134(36%)vs BAT组4/67(6%),差值30%(95%CI 20-39;单侧P<0.0001)。

要点

  • 第6周期末SVR35:fedratinib组36% vs BAT组6%,差值30%(95%CI 20-39)。
  • ≥3级治疗相关不良事件:fedratinib组40% vs BAT组12%,常见为贫血和血小板减少。
  • fedratinib组1例死于疑似与研究药物相关的急性肾损伤,BAT组无治疗相关死亡。

核心结论

  • FREEDOM2结果支持fedratinib作为ruxolitinib失败或不耐受后减少脾脏大小的二线Janus激酶抑制剂选择。
  • 研究显示通过预防、监测和治疗可有效管理胃肠道不良事件和低硫胺素浓度。

研究设计与样本

  • FREEDOM2为在16个国家86家诊所开展的多中心、开放标签、随机对照3期试验。
  • 纳入年龄≥18岁、中危-2或高危骨髓纤维化、对ruxolitinib复发或难治或不耐受、ECOG体能状态0-2的患者。
  • 按脾脏触诊大小、血小板计数和既往ruxolitinib治疗分层,经交互响应技术按2:1随机分配接受fedratinib 400 mg/日(4×100 mg胶囊口服,每日一次,开放标签)或BAT。
  • 患者接受预防性止吐药和硫胺素补充,必要时使用对症止泻药。
  • 主要终点为意向治疗人群中第6周期末达到脾体积缩小≥35%(SVR35)的患者比例。

主要发现

  • 2019年9月9日至2022年6月24日筛查316例患者,201例随机分配并治疗(fedratinib组134例,BAT组67例,其中52例接受ruxolitinib);BAT组46例交叉至fedratinib。
  • 入组患者中约半数男性(fedratinib组75/134[56%];BAT组30/67[45%]),多数为白人(fedratinib组106/134[79%];BAT组58/67[87%])。
  • 数据截止2022年12月27日,中位生存随访64.5周(IQR 37.9-104.9)。
  • 第6周期末SVR35:fedratinib组48/134(36%)vs BAT组4/67(6%),差值30%(95%CI 20-39;单侧P<0.0001)。
  • 前6周期≥3级治疗相关不良事件:fedratinib组53/134(40%)vs BAT组8/67(12%);最常见为贫血(fedratinib组12/134[9%] vs BAT组6/67[9%])和血小板减少(fedratinib组16/134[12%] vs BAT组2/67[3%])。

关键数值与推荐

  • 主要终点SVR35(第6周期末):fedratinib组36% vs BAT组6%,差值30%(95%CI 20-39;单侧P<0.0001)。
  • ≥3级治疗相关不良事件(前6周期):fedratinib组40% vs BAT组12%。
  • 贫血(≥3级治疗相关):fedratinib组9% vs BAT组9%;血小板减少:fedratinib组12% vs BAT组3%。
  • 硫胺素低于正常下限:fedratinib组21% vs BAT组4%。

临床怎么用

  • 作者认为FREEDOM2结果支持fedratinib作为ruxolitinib失败或不耐受后减少脾脏大小的二线Janus激酶抑制剂选择。
  • 作者认为通过预防、监测和治疗可有效管理胃肠道不良事件和低硫胺素浓度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients with myelofibrosis develop ruxolitinib intolerance or disease that is relapsed or refractory, and survival rates after ruxolitinib discontinuation are poor. We aimed to evaluate the safety and efficacy of fedratinib versus best available therapy (BAT) in patients with myelofibrosis previously treated with ruxolitinib. METHODS: FREEDOM2 was a multicentre, open-label, randomised, controlled, phase 3 trial in 86 clinics in 16 countries, in which patients aged at least 18 years with intermediate-2 or high-risk myelofibrosis that was relapsed or refractory or intolerant to ruxolitinib with Eastern Cooperative Oncology Group performance status 0-2 were stratified by spleen size by palpation, platelet count, and previous ruxolitinib treatment, and randomly assigned 2:1 by interactive response technology to receive fedratinib 400 mg per day (4 × 100 mg capsules orally once daily, open-label) or BAT. Patients received prophylactic antiemetics and thiamine supplementation, and symptomatic antidiarrhoeals as required. Primary endpoint was proportion of patients reaching spleen volume reduction (SVR) of at least 35% (SVR35) at end of cycle 6 in the intention-to-treat population. This manuscript reports the primary analysis of the trial; follow-up is ongoing. This trial is registered at clinicaltrials.gov, NCT03952039. FINDINGS: Between Sept 9, 2019 and June 24, 2022, of 316 patients screened, 201 were randomly assigned and treated (134 to fedratinib, 67 to BAT [including 52 receiving ruxolitinib]); 46 patients from the BAT group crossed over to fedratinib. Approximately half of enrolled patients were male (fedratinib 75 [56%] of 134; BAT 30 [45%] of 67) and most were White (fedratinib 106 [79%] of 134; BAT 58 [87%] of 67). At data cutoff (Dec 27, 2022), median survival follow-up was 64·5 weeks (IQR 37·9-104·9). SVR35 at end of cycle 6 was seen in 48 (36%) of 134 patients receiving fedratinib versus four (6%) of 67 patients receiving BAT (30% difference; 95% CI 20-39; one-sided p-value <0·0001). During the first six cycles 53 (40%) of 134 patients in the fedratinib group and 8 (12%) of 67 patients in the BAT group had grade 3 or greater treatment-related adverse events, most frequently anaemia (fedratinib 12 [9%] of 134; BAT 6 [9%] of 67) and thrombocytopenia (fedratinib 16 [12%] of 134; BAT 2 [3%] of 67); one patient in the fedratinib group died from acute kidney injury suspected to be related to study drug (no treatment-related deaths in the BAT group). Gastrointestinal adverse events occurred more frequently in the fedratinib group compared with the BAT group, but were mostly grade 1-2 in severity and more frequent in early cycles, and were less frequent than in prior clinical trials. A total of 28 (21%) of 134 patients in the fedratinib group and 3 (4%) of 67 patients in the BAT group had thiamine levels below lower limit of normal per central laboratory assessment, with only one case of low thiamine in the fedratinib arm after the introduction of prophylactic thiamine supplementation. INTERPRETATION: Findings from FREEDOM2 support fedratinib as a second-line Janus kinase inhibitor option to reduce spleen size after ruxolitinib failure or intolerance in patients with myelofibrosis, and shows effective strategies for management of gastrointestinal adverse events and low thiamine concentrations through prophylaxis, monitoring, and treatment. FUNDING: Bristol Myers Squibb.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Harrison CN, Mesa R, Talpaz M, et al. Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Haematol. 2024. PMID: 39265613. doi:10.1016/S2352-3026(24)00212-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。